The Safety and Effectiveness of Cidofovir in the Treatment of Venereal Warts in HIV-Infected Patients

Inclusion Criteria Concurrent Medication: Allowed: AZT, ddI, ddC, d4T, or 3TC. Oral trimethoprim/sulfamethoxazole. Aerosolized pentamidine. Dapsone. Fluconazole. Rifabutin. Clarithromycin. Patients must have: HIV seropositivity. Mean CD4 count >= 100 cells/mm3. External anogenital condyloma acuminatum confirmed by biopsy, present for less than 1 year. NOTE: Warts on anal, urethral, or vaginal mucosa will not be studied. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Active lesions of genital herpes, other skin wounds, or active inflammatory skin disorders in the same area as warts to be treated. Active medical problems sufficient to hinder study compliance. Concurrent Medication: Excluded: Podofilox or any podophyllum resin preparation. Liquid nitrogen treatment. Interferon alpha. Trichloracetic acid. Other treatments, topical or systemic, surgical or ablative, known to have anti-papilloma activity. Other investigative drugs (except d4T or 3TC) unless approved by the sponsor. Patients with the following prior conditions are excluded: History of untreated syphilis or Bowenoid papulosis. Prior Medication: Excluded within 4 weeks prior to study entry: Treatment for anogenital warts. Immunomodulators (including interferons or systemic corticosteroids). Lymphocyte replacement therapy. Biologic response modifiers. Substance abuse.